Advertisement

Inflammation

, Volume 42, Issue 6, pp 2086–2094 | Cite as

Effect of Oral T2 Antigen on Chronic Prostatitis/Chronic Pelvic Pain Syndrome in Mice Model

  • Meng Tang
  • Rahat Ullah
  • Junaid Wazir
  • Farhan Ullah Khan
  • Awais Ullah Ihsan
  • Xingxing Cui
  • Wenlu Wang
  • Min Hu
  • Yuqian Liu
  • Xiaohui ZhouEmail author
Original Article
First Online:
  • 88 Downloads

Abstract

The exact etiology and pathogenesis of chronic prostatitis (CP/CPPS) remain unclear. However, autoimmunity is a widely known theory. Precise treatment of CP/CPPS is not available. Here, we developed a new effective treatment method to prevent the occurrence of CP/CPPS. A total of 40 male C57BL/6 mice were randomly divided into four groups (n = 10): i.e., naive, model, high-dose (500 μg/ml), and low-dose (50 μg/ml) groups. High-dose and low-dose groups were orally given 0.4 ml of T2-containing soybean trypsin inhibitor (STI) at once after every 2 days for a total of 10 days. On day 10 and day 24 all the groups except naïve group were subcutaneously injected with 0.2 ml of T2 peptide along with CFA to make valid CP/CPPS models. Hematoxylin and eosin staining were used to evaluate the variation in CP/CPPS manifestation. Voiding behavior was recorded for the evaluation of urine frequencies. ELISA was used to measure the serum level of TNF-α in each group. The high- and low-dose groups of T2-containing STI displayed a reduction in urine frequencies, and inflammation, and there was a slight inflammatory infiltration as compared to the model group. In contrast, there was no difference observed in the TNF-α concentration of model as well as high- and low-dose groups compared to the naïve group. Our study demonstrates that oral T2-containing STI prevents CP/CPPS and provides an effective approach for the treatment of CP/CPPS.

KEY WORDS

T2 antigen oral tolerance chronic prostatitis/chronic pelvic pain syndrome inflammation 
This is a preview of subscription content, log in to check access.

Notes

Author’s Contributions

Meng Tang, Rahat Ullah, and Junaid Wazir designed the study; Meng Tang and Rahat Ullah performed the experiments and wrote the manuscript; Xinxing Cui and Wenlu Wang contributed to the establishment of mice model. Min Hu and Yuqian Liu helped analyze the data; Farhan Ullah Khan and Awais Ullah Ihsan revised the manuscript; Xiaohui Zhou supervised the whole study.

Funding information

This work was supported by the National Natural Science Foundation of China [Grant Nos. 30973003 & 30901993] and Administration of TCM of Jiangsu province [Grant No. LZ11093].

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Alexander, R.B., S. Ponniah, J. Hasday, and J.R. Hebel. 1998. Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome. Urology 52 (5): 744–749.CrossRefGoogle Scholar
  2. 2.
    Assoian, R.K., B.E. Fleurdelys, H.C. Stevenson, P.J. Miller, D.K. Madtes, E.W. Raines, R. Ross, and M.B. Sporn. 1987. Expression and secretion of type beta transforming growth factor by activated human macrophages. Proceedings of the National Academy of Sciences of the United States of America 84 (17): 6020–6024.CrossRefGoogle Scholar
  3. 3.
    Bitar, D.M., and C.C. Whitacre. 1988. Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. Cellular Immunology 112 (2): 364–370.CrossRefGoogle Scholar
  4. 4.
    Chen, H., L. Zhang, W.G. Hill, and W. Yu. 2017. Evaluating the Voiding Spot Assay in Mice: A Simple Method With Complex Environmental Interactions. American Journal of Physiology. Renal Physiology 313 (6): ajprenal.00318.02017.CrossRefGoogle Scholar
  5. 5.
    Cheng, Y., Y. Cao, A.U. Ihsan, F.U. Khan, X. Li, D. Xie, X. Cui, W. Wang, Z. Liu, C. Li, K.A. Ahmad, K.R. Sembatya, R. Mikrani, and X. Zhou. 2019. Novel Treatment of Experimental Autoimmune Prostatitis by Nanoparticle-Conjugated Autoantigen Peptide T2. Inflammation 42 (3): 1071–1081.  https://doi.org/10.1007/s10753-019-00968-5.CrossRefPubMedGoogle Scholar
  6. 6.
    Cohen, J.M., A.P. Fagin, E. Hariton, J.R. Niska, M.W. Pierce, A. Kuriyama, J.S. Whelan, J.L. Jackson, and J.D. Dimitrakoff. 2012. Therapeutic intervention for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a systematic review and meta-analysis. PLoS One 7 (8): e41941.  https://doi.org/10.1371/journal.pone.0041941.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Collins, M.M., R.S. Stafford, M.P. O'Leary, and M.J. Barry. 1998. How common is prostatitis? A national survey of physician visits. Journal of Urology 159 (4): 1224–1228.CrossRefGoogle Scholar
  8. 8.
    Faria, A.M., and H.L. Weiner. 2006. Oral tolerance: therapeutic implications for autoimmune diseases. Clinical & Developmental Immunology 13 (2–4): 143–157.CrossRefGoogle Scholar
  9. 9.
    Higgins, P.J., and H.L. Weiner. 1988. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. Journal of Immunology 140 (2): 440–445.Google Scholar
  10. 10.
    Ihsan, A.U., F.U. Khan, W. Nawaz, M.Z. Khan, M. Yang, and X. Zhou. 2017. Establishment of a rat model of chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) induced by immunization with a novel peptide T2. Biomedicine & Pharmacotherapy 91: 687–692.  https://doi.org/10.1016/j.biopha.2017.05.004.CrossRefGoogle Scholar
  11. 11.
    John, H., A. Barghorn, G. Funke, T. Sulser, S. Hailemariam, D. Hauri, and H. Joller-Jemelka. 2001. Noninflammatory chronic pelvic pain syndrome: immunological study in blood, ejaculate and prostate tissue. European Urology 39 (1): 72–78.CrossRefGoogle Scholar
  12. 12.
    Khan, Farhan Ullah, Awais Ullah Ihsan, Waqas Nawaz, Muhammad Zahid Khan, Mengqi Yang, Gang Wang, Xiaoqian Liao, Lei Han, and Xiaohui Zhou. 2017. A novel mouse model of chronic prostatitis/chronic pelvic pain syndrome induced by immunization of special peptide fragment with aluminum hydroxide adjuvant. Immunology Letters 187: S0165247817301669.CrossRefGoogle Scholar
  13. 13.
    Kim, S.J., J.H. Kehrl, J. Burton, C.L. Tendler, K.T. Jeang, D. Danielpour, C. Thevenin, K.Y. Kim, M.B. Sporn, and A.B. Roberts. 1990. Transactivation of the transforming growth factor beta 1 (TGF-beta 1) gene by human T lymphotropic virus type 1 tax: a potential mechanism for the increased production of TGF-beta 1 in adult T cell leukemia. Journal of Experimental Medicine 172 (1): 121–129.CrossRefGoogle Scholar
  14. 14.
    Krieger, J.N., L. Nyberg, and J.C. Nickel. 1999. NIH consensus definition and classification of prostatitis. JAMA 282 (3): 236–237.CrossRefGoogle Scholar
  15. 15.
    Li, Lequn, and Vassiliki A. Boussiotis. 2006. Physiologic regulation of central and peripheral T cell tolerance: lessons for therapeutic applications. Journal of Molecular Medicine 84 (11): 887–899.CrossRefGoogle Scholar
  16. 16.
    Li, Meng, Jinhu Wu, and Yonggang Chen. 2012. Advances in animal models of prostatitis. Medical Review 18 (4): 567–570.Google Scholar
  17. 17.
    Lloyd, Mayer, and Ling Shao. 2004. Therapeutic potential of oral tolerance. Nature Reviews Immunology 4 (6): 407–419.CrossRefGoogle Scholar
  18. 18.
    Mahal, Brandon A., Jeffrey M. Cohen, Stephen A. Allsop, John B. Moore, Salman F. Bhai, Gino Inverso, and Jordan D. Dimitrakoff. 2011. The role of phenotyping in chronic prostatitis/chronic pelvic pain syndrome. Current Urology Reports 12 (4): 297–303.CrossRefGoogle Scholar
  19. 19.
    Maron, R., M. Guerau-de-Arellano, X. Zhang, and H.L. Weiner. 2001. Oral administration of insulin to neonates suppresses spontaneous and cyclophosphamide induced diabetes in the NOD mouse. Journal of Autoimmunity 16 (1): 21–28.  https://doi.org/10.1006/jaut.2000.0471.CrossRefPubMedGoogle Scholar
  20. 20.
    Miller, A., O. Lider, A.B. Roberts, M.B. Sporn, and H.L. Weiner. 1992. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proceedings of the National Academy of Sciences of the United States of America 89 (1): 421–425.CrossRefGoogle Scholar
  21. 21.
    Nagler-Anderson, C., L.A. Bober, M.E. Robinson, G.W. Siskind, and G.J. Thorbecke. 1986. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proceedings of the National Academy of Sciences of the United States of America 83 (19): 7443–7446.  https://doi.org/10.1073/pnas.83.19.7443.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Nussenblatt, R.B., R.R. Caspi, R. Mahdi, C.C. Chan, F. Roberge, O. Lider, and H.L. Weiner. 1990. Inhibition of S-antigen induced experimental autoimmune uveoretinitis by oral induction of tolerance with S-antigen. Journal of Immunology 144 (5): 1689–1695.Google Scholar
  23. 23.
    Pontari, Michel A., and Michael R. Ruggieri. 2008. Mechanisms in Prostatitis/Chronic Pelvic Pain Syndrome. Journal of Urology 179 (5): S61–S67.PubMedGoogle Scholar
  24. 24.
    Rivero, Virginia E., Pablo Iribarren, and Clelia M. Riera. 1995. Mast Cells in Accessory Glands of Experimentally Induced Prostatitis in Male Wistar Rats. Clinical Immunology and Immunopathology 74 (3): 236–242.CrossRefGoogle Scholar
  25. 25.
    Schaeffer, Anthony J. 2008. Epidemiology and evaluation of chronic pelvic pain syndrome in men. J International journal of antimicrobial agents 31: 108–111.CrossRefGoogle Scholar
  26. 26.
    Sricharunrat, T., P. Pumirat, and P. Leaungwutiwong. 2018. Oral tolerance:Recent advances on mechanisms and potential applications. Asian Pacific Journal of Allergy and Immunology 36 (4): 207–216.  https://doi.org/10.12932/ap0848.CrossRefPubMedGoogle Scholar
  27. 27.
    Thompson, S.J., H.S. Thompson, N. Harper, M.J. Day, A.J. Coad, C.J. Elson, and N.A. Staines. 1993. Prevention of pristane-induced arthritis by the oral administration of type II collagen. Immunology 79 (1): 152–157.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Wang, Z.Y., J. Qiao, and H. Link. 1993. Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor. Journal of Neuroimmunology 44 (2): 209–214.CrossRefGoogle Scholar
  29. 29.
    Wu, Zaide, and Wu Yuhan. 2004. Surgery [M]. 6th ed, 683–684. Beijing: People’s Medical Publishing House.Google Scholar
  30. 30.
    Weiner, Howard L, Andre Pires da Cunha, Francisco Quintana, and Henry Wu. 2011. Oral tolerance. Immunological reviews 241 (1):241-259.CrossRefGoogle Scholar
  31. 31.
    Xiaofeng, Han. 2001. Progress in the mechanism and application of oral tolerance. International Journal of Immunology 24 (5): 265–268.Google Scholar
  32. 32.
    Xiaohui, Zhou, Han Lei, Zhou Zhiheng, Liu Zhongde, Yang Jixiang, Lu Yanwei, and You Chunlai. 2005. Morphological and molecular biological characteristics of a rat model of immune chronic nonbacterial prostatitis. Chinese Journal of Andrology: 290–295.Google Scholar
  33. 33.
    Yanqun, A., Ye Zhangqun, and Sun Yinghao. 2014. Guidelines for the diagnosis and treatment of urological diseases in China. Beijing: People’s Health Publishing House.Google Scholar
  34. 34.
    Zhang, L., A.U. Ihsan, Y. Cao, Y. Cheng, and X. Zhou. 2017. Establishment of experimental autoimmune prostatitis model by T2 peptide in aluminium hydroxide adjuvant. Andrologia 50: 5.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Meng Tang
    • 1
  • Rahat Ullah
    • 1
  • Junaid Wazir
    • 1
  • Farhan Ullah Khan
    • 1
  • Awais Ullah Ihsan
    • 1
  • Xingxing Cui
    • 1
  • Wenlu Wang
    • 1
  • Min Hu
    • 1
  • Yuqian Liu
    • 1
  • Xiaohui Zhou
    • 1
    • 2
    • 3
    Email author
  1. 1.Department of Clinical Pharmacy, School of Basic Medicine and Clinical PharmacyChina Pharmaceutical UniversityNanjingChina
  2. 2.Department of SurgeryNanjing Shuiximen HospitalNanjingChina
  3. 3.Zhongda HospitalAffiliated with Southeast UniversityNanjingChina

Personalised recommendations

Cite article

Buy options